Amyloid precursor protein gene mutated at Swedish 670/671 sites in vitro induces changed expression of nicotinic acetylcholine receptors and neurotoxicity

Neurochemistry International

Volumn 57, Issue 6, 2010, Pages 647-654

  An, Yu ^a   Qi, Xiao Lan ^a   Pei, Jin Jing ^b   Tang, Zhi ^a   Xiao, Yan ^a   Guan, Zhi Zhong ^a,b  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

APPSWE; Nicotinic acetylcholine receptor; Primary culture neurons; SH SY5Y cells

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID PRECURSOR PROTEIN; BUNGAROTOXIN RECEPTOR; CHOLINERGIC RECEPTOR; CHOLINESTERASE; COMPLEMENTARY DNA; EPIBATIDINE; MESSENGER RNA; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA3; NICOTINIC RECEPTOR ALPHA4; PROTEIN SUBUNIT; RECEPTOR SUBUNIT; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRITIUM; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BINDING SITE; BIOLOGICAL ACTIVITY; CELL CULTURE; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VITRO STUDY; LIPID PEROXIDATION; NERVE CELL; NEUROBLASTOMA CELL; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING; WESTERN BLOTTING;

ACETYLCHOLINESTERASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; BUTYRYLCHOLINESTERASE; CELL LINE; DNA PRIMERS; HUMANS; LIPID PEROXIDATION; MUTATION; POLYMERASE CHAIN REACTION; RATS; RECEPTORS, NICOTINIC; RNA, MESSENGER; TRANSFECTION;

RATTUS;

EID: 77957019415     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.08.001     Document Type: Article

References (46)

1. Allinquant B., Hantraye P., Mailleux P., Moya K., Bouillot C., Prochiantz A. Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J. Cell Biol. 1995, 128:919-927.
2. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
3. Caporaso G.L., Gandy S.E., Buxbaum J.D., Greengard P. Chloroquine inhibits intracellular degradation but not secretion of Alzheimer beta/A4 amyloid precursor protein. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:2252-2256.
4. Cole S.L., Vassar R. The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. J. Biol. Chem. 2008, 283:29621-29625.
5. Delacourte A., Sergeant N., Wattez A., Maurage C.A., Lebert F., Pasquier F., David J.P. Tau aggregation in the hippocampal formation: an ageing or a pathological process?. Exp. Gerontol. 2002, 37:1291-1296.
6. Dineley K.T., Bell K.A., Bui D., Sweatt J.D. Beta-amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J. Biol. Chem. 2002, 77:25056-25061.
7. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
8. Gerzanich V., Peng X., Wang F., Wells G.A., Fletcher S., Lindstrom J. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol. Pharmacol. 1995, 48:774-782.
9. Geula C., Nagykery N., Nicholas A., Wu C.K. Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2008, 67:309-318.
10. Gil-Bea F.J., Garcia-Alloza M., Dominguez J., Marcos B., Ramói{dotless}rez M.J. Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit. Neurosci. Lett. 2005, 375:37-41.
11. Götz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293:1491-1495.
12. Götz J., Schild A., Hoerndli F., Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int. J. Dev. Neurosci. 2004, 22:453-465.
13. Götz J., Ittner L.M., Schonrock N., Cappai R. An update on the toxicity of Abeta in Alzheimer's disease. Neuropsychiatr. Dis. Treat. 2008, 4:1033-1042.
14. Goate A., Chartier-Harllin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C., Pericak-Vance M., Roses A., Williamson R., Rossor M., Owen M., Hardy J. Segregatio of a missense mutation in the amyloid precursor protein gene with familial alzeimer's disease. Nature 1991, 349:704-706.
15. Greig N.H., Utsuki T., Yu Q., Zhu X., Holloway H.W., Perry T., Lee B., Ingram D.K., Lahiri D.K. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr. Med. Res. Opin. 2001, 17:59-165.
16. Greig N.H., Lahiri D.K., Sambamurti K. Butyrylcholinesterase: an important newtarget in Alzheimer's disease therapy. Int. Psychogeriatri. 2002, 14:77-91.
17. Guan Z.Z. Cross-talk between oxidative stress and modifications of cholinergic and glutaminergic receptors in the pathogenesis of Alzheimer's disease. Acta Pharmacol. 2008, 29:773-780.
18. Guan Z.Z., Zhang X., Ravid R., Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J. Neurochem. 2000, 74:237-243.
19. Guan Z.Z., Miao H., Tian J.Y., Unger C., Nordberg A., Zhang X. Suppressed expression of nicotinic acetylcholine receptors by nanomolar beta-amyloid peptides in PC12 cells. J. Neural. Transm. 2001, 108:1417-1433.
20. Gunawardena S., Goldstein L.S. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron 2001, 32:389-401.
21. Hamel E., Nicolakakis N., Aboulkassim T., Ongali B., Tong X.K. Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer's disease. Exp. Physiol. 2008, 93:116-120.
22. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
23. Kamal A., Almenar-Queralt A., LeBlanc J.F., Roberts E.A., Goldstein L.S. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 2000, 414:643-648.
24. Kulic L., Kurosinski P., Chen F., Tracy J., Mohajeri M.H., Li H., Nitsch R.M., Götz J. Active immunization trial in Abeta42-injected P301L tau transgenic mice. Neurobiol. Dis. 2006, 22:50-56.
25. Lane R.M., Potkin S.G., Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int. J. Neuropsychopharmacol. 2006, F9:101-124.
26. Liu R.Y., Gu Y., Qi X.L., Zhang T., Zhao Y., He Y., Pei J.J., Guan Z.Z. Decreased nicotinic receptors and cognitive deficit in rats intracerebroventricularly injected with beta-amyloid peptide(1-42) and fed a high-cholesterol diet. J. Neurosci. Res. 2008, 86:183-193.
27. Mousavi M., Hellström-Lindahl E. Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. Neurochem. Int. 2008, 54:237-244.
28. Mousavi M., Nordberg A. Expression of the alpha7, alpha4 and alpha3 nicotinic receptor subtype in the brain and adrenal medulla of transgenic mice carrying genes coding for human AChE and beta-amyloid. Int. J. Dev. Neurosci. 2006, 24:269-273.
29. Mullan M., Crawford F., Axelman k., Houlden H., Lilius L., Winblad B., Lannfelt L. A pathogenic mutation for probable alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nat. Genet. 1992, 1:345-347.
30. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol. Psychiatry 2001, 49:200-210.
31. O'Neill M.J., Murray T.K., Lakics V., Visanji N.P., Duty S. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr. Drug. Targets. CNS Neurol. Disord. 2002, 1:399-411.
32. Paterson D., Nordberg A. Neuronal nicotinic receptors in the human brain. Progr. Neurobiol. 2000, 61:75-111.
33. Patocka J., Kuca K., Jun D. Acetylcholinesterase and butyrylcholinesterase-important enzymes of human body. Acta Medica (Hradec Kralove) 2004, 47:215-228.
34. Qi X.L., Xiu J., Shan K.R., Xiao Y., Gu R., Liu R.Y., Guan Z.Z. Oxidative stress induced by beta-amyloid peptide(1-42) is involved in the altered composition of cellular membrane lipids and the decreased expression of nicotinic receptors in human SH-SY5Y neuroblastoma cells. Neurochem. Int. 2005, 46:613-621.
35. Qi X.L., Nordberg A., Xiu J., Guan Z.Z. The consequences of reducing expression of the α7 nicotinic receptor by RNA interference and of stimulating its activity with an α7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease. Neurochem. Int. 2007, 51:377-383.
36. Roensch J., Crisby M., Nordberg A., Xiao Y., Zhang L.J., Guan Z.Z. Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells. Neurochem. Int. 2007, 50:800-806.
37. Sakono M., Zako T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J. 2010, 277:1348-1358.
38. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron 2001, 32:177-180.
39. Sharma G., Vijayaraghavan S. Nicotinic receptor signaling in nonexcitable cells. Neurobiology 2002, 53:524-525.
40. Tang Z., An Y., Qi X.L., Xiao Y., Shan K.R., Guan Z.Z. Inhibiting gene expression of alpha3 nicotinic receptor in SHSY5Y cells with the effects on APP metabolism and antioxidation in Alzheimer's disease. Neurochem. Int. 2008, 53:112-117.
41. von-Bernhardia R., Alarcona R., Mezzanob D., Fuentes P., Inestrosa N.C. Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia. Dement. Geriatr. Cogn. Disord. 2005, 19:204-212.
42. Weidemann A., Konig G., Bunke D., Fischer P., Salbaum J.M., Masters C.L., Beyreuther K. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 1989, 57:115-126.
43. Wevers A., Monteggia L., Nowacki S., Bloch W., Schutz U., Lindstrom J., Pereira E.F., Eisenberg H., Giacobini E., de Vos R.A., Steur E.N., Maelicke A., Albuquerque E.X., Schroder H. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur. J. Neurosci. 1999, 11:2551-2565.
44. Wevers A., Burghaus L., Moser N., Witter B., Steinlein O.K., Schutz U., Achnitz B., Krempel U., Nowacki S., Pilz K., Stoodt J., Lindstrom J., DeVos R.A., Jansen Steur E.N., Schroder H. Expression of nicotinic acetylcholine receptors in Alzheimer's disease: postmortem investigations and experimental approaches. Behav. Brain. Res. 2000, 113:207-215.
45. Xiu J., Nordberg A., Qi X.L., Guan Z.Z. Influence of cholesterol and lovastatin on alpha-form of secreted amyloid precursor protein and expression of alpha7 nicotinic receptor on astrocytes. Neurochem. Int. 2006, 49:459-465.
46. Yu W.F., Guan Z.Z., Bogdanovic N., Nordberg A. High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp. Neurol. 2005, 192:215-225.